Back ground: Adipose tissue plays a crucial role in regulation of lipid and carbohydrate metabolism and many of these actions are regulated by insulin. Objective: The present study aims to detect potential novel protein targets for insulin sensitization in human adipose tissue by using an unbiased proteomic approaches. Method: Ten moderately obese, but otherwise healthy, subjects were treated with rosiglitazone 4 mg BD for 14 days. Protein profiles were obtained by two-dimensional gel (2-DG) electrophoresis and protein spots were identified using tandem mass spectrometry. Data were analyzed statistically by using student's paired t test. Results: Proteomic analysis revealed distinct up or down regulation (> 2-fold) in 122 protein spots on the 2-D gel images between day 0 and day 14 adipose tissue samples. Treatment with rosiglitazone increased the expression of extracellular matrix proteins including collagens, galectin-1, nidogen-1 and laminin. Analysis revealed differential expression of several other proteins involved in redox regulation (ferritin light chain, heat-shock protein β-5, heatshock protein β-1), endoplasmic reticulum (ER) stress (endoplasmin, 78 kDa glucose-regulated protein precursor), cytoskeletal reorganization (lamin A/C, vimentin, tropomyosin-3, tropomyosin-4, gelsolin, actin tubulin β-1 chain), signaling (calmodulin), and others (glyceraldehyde-3-phosphate dehydrogenase, α enolase). Conclusion: Such orchestrated changes in expression of multiple proteins provide insights into the mechanism undarlying the increased efficiency in adipocyte remodeling and differentiation and hence improvement of insulin sensitivity in response to rosiglitazone treatment.
homeostasis, therefore contribute to increased insulin sensitivity [1] [2] [3] . PPARã is predominantly expressed in adipose tissue in both rodents and humans and a substantial number of studies have described changes in gene expression in adipose tissue in response to rosiglitazone treatment 2 . Stimulation of PPARã by fatty acids or TZD results in expression of markers associated with preadipocyte differentiation [4] [5] [6] . It has also been suggested that adipose tissue dysfunction and impaired adipogenesis is causally related to systemic insulin resistance 7, 8 . In obesity and in non-obese insulin-resistant subjects, ne of the prime targets for the treatment of diabetes is to enhance the insulin sensitivity so that the tissues can precisely utilize glucose and keep its plasma level within physiological limit. Rosiglitazone, a member of the thiazolidinedione (TZD) class of antidiabetic agents, improves insulin sensitivity both in liver and peripheral tissues 1 . TZDs bind to and activate the peroxisome proliferator activated receptor (PPARã), a nuclear receptor and regulate the co ordinated expression of multiple genes that integrates the control of energy, glucose and lipid O J Bangladesh Soc Physiol. 2009 Dec;4(2): [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] adipogenesis is impaired which leads to an increased energy partitioning to existing adipocytes and consequently the fat cells are enlarged 8, 9 . However, it is largely unclear how the functional consequences of PPARg activation lead to processes that can help to explain the insulin sensitization, especially in vivo in humans. In this context, the successful application of proteomic approaches is likely to identify some of the mechanisms behind the failure of insulin to act on adipocytes and development of type 2 diabetes. Using combined proteomic approaches we have previously shown that improved insulin sensitivity is coupled to upregulation of glucose uptake in human adipose tissue 10 .
In the present comparative proteomic study global protein profiles of the human adipose tissue were obtained by 2D gel electrophoresis and differentially expressed proteins in response to rosiglitazone were identified by tandem mass spectrometry. We, for the first time, provide evidence that improvement of insulin sensitivity in response to rosiglitazone treatment is associated with simultaneous changes in expression of multiple proteins involved in differentiation of adipocytes, cytoskeletal rearrangement, calcium signaling, ER stress, lipid droplet stabilization and fatty acid metabolism in adipose tissue. The orchestrated changes in protein expression pattern in human adipose tissue primarily promote adipogenesis and thus improve insulin sensitivity.
Methods

Subjects:
Ten healthy, in the range of being overweight or obese, male subjects aged 20 60 years participated in this study. Entry criteria included fasting plasma glucose of < 7.0 mmol/l and a BMI ranging between 25 45 kg/m 2 . Patients with type 2 diabetes, heart failure and any with chronic disease that might interfere with outcome oral hypoglycemic agents were excluded, as were those taking any medication known to affect glucose metabolism. The study was approved by the Oxford Research Ethics Committee and all subjects gave their written informed consent.
Study design: Blood samples (antecubital venous, 20 ml blood per visit), blood pressure and anthropometric measurements were made first while the participants attended the Clinical Research Unit, OCDEM in the morning, after a 12 hour fast. Abdominal subcutaneous adipose tissue biopsies were taken with a 12 gauge needle under local anesthesia (1% lidocaine) in the fasted state at day 0 (baseline, without medication) and thereafter the participants were treated with rosiglitazone (Glaxo SmithKline) 4 mg twice daily. The volunteer returned for blood samples, anthropometric measurements and biopsies on day 14 after start of the medication. Fasting plasma triglyceride, NEFA, glucose and insulin concentrations were measured as described previously 11 .
Protein sample preparation and two dimensional gel electrophoresis: Adipose tissue protein was precipitated and isolated from the phenol ethanol supernatant obtained during RNA isolation according to the protocol (Molecular Research Center, Inc). The protein pellets were further treated with the Plus One 2 D Clean Up Kit (Amersham Biosciences) and later solubilized in buffer containing 7M urea, 2M thiourea, 0.5% Triton X 100, 4% CHAPS, 0.5% pharmalyte (pH 3 10), 0.1% NP 7, 5% glycerol, 10% isopropanol, protease inhibitor cocktail and 60 mM DTT. Protein concentration was determined using the 2 D Quant Kit (Amersham Biosciences) and 250 µg protein samples were loaded onto the immobiline dry strips, pH 3 11 NL (Amersham Biosciences). The rehydrated strips were focused on the Protean IEF Cell (Bio Rad) for about 12 kVh at a maximum of 6,000 V in rapid voltage ramping mode with a maximum current per strip of 30 µA.
Equilibration of the IPG strips was performed in two steps: reduction followed by alkylation 12, 13 . The second dimension was run on 8 16% precast polyacrylamide SDS gels (8.7 × 13.3 × 0.1 cm; BioRad Dodeca cell) at room temperature with a constant voltage of 120 V for 10 min, followed by 200 V until the dye has migrated off the lower end of the gel.
Protein visualization and image analysis:
The 2 D analytical gels (n = 12) were stained with fluorescent dye SYPRO Ruby (BioRad) according to the manufacturer. The 2 D preparative gels (n = 2) were visualized with Bio Safe Coomassie stain (Bio Rad). The stained analytical gels were imaged using Molecular Imager FX Pro Fluorescent Imager (Bio Rad). Raw scans were processed by the 2 D gel analysis software, PDQuest version 8.0.1 (Bio Rad) as previously described 13 . For reliable matching 21 different landmark proteins were manually added in each gel. Significant changes between spots were determined using Student's t test for paired observations. Changes with a p value of < 0.05 were considered as being statistically significant.
Protein identification by tandem mass spectrometry:
Protein spots with consistent presence in 2D analytical gels of replicate groups (day 0 and day 14) were selected and excised manually from preparative gels (n=2), and transferred to 1.5 mL Eppendorf tubes. Individual gel spots were subjected to in-gel trypsin digestion. Protein digests were analyzed by electrospray ionization liquid chromatography tandem mass spectrometry (ESI LC MS/MS) using a high capacity iontrap (HCTplus TM , Bruker Daltonics, Bremen, Germany) tandem mass spectrometer 14 . Liquid chromatography was performed using an Ultimate TM (LC Packings, Dionex, Netherlands) system equipped with a Famos TM auto sampler. Samples were concentrated on a trapping column (300 µm i.d., 1 cm, LC Packings) at a flow rate of 25 µL/min. For the separation with a C18 PepMap column (75 µm i.d., 10 cm, LC Packings) a flow rate of 200 nL/min was used. For electrospray ionization, we used coated silica Picotips TM (New Objective, MA, USA). Instruments were controlled using HyStar TM 3.0 and EsquireControl TM 5.2 (Bruker Daltonics) software. The sample injection volume used in all experiments was 5 µL and tuning parameters of the mass spectrometer were kept as constant as possible.
Individual MS/MS spectra were searched against Swissprot/NCBInr using Mascot TM software (Matrixscience, London, UK). The interpretation and presentation of MS/MS data were performed according to published guidelines 15 . The peptide and fragment mass tolerances were 2.5 and 0.8 Da, respectively. Identification was based on the presence of at least two peptides and on Mascot scores of higher than 50.
Western blot analysis:
Equal amounts of protein (10 µg) were separated by SDS PAGE (12.5%), transferred to a polyvinylidene difluoride membrane, and blotted with primary antibody containing 1% milk and 0.05% Tween 20. Primary antibodies used in this study were lamin A/C (1:1000; Santa Cruz Biotechnology, Santa Cruz, California), and protein disulfide isomerase (PDI; 1:1000; Santa Cruz Biotechnology). The membranes were incubated for 60 minutes with horseradish peroxidase-conjugated antimouse and antirabbit IgG (1:20,000). Immunodetection was performed using enhanced chemifluorescence detection according to the manufacturer's protocol (Amersham Biosciences). Briefly, chemifluorescence detection reagents were applied for 1 minute and chemifluorescence was detected using the AutoChemi System (UVP BioImaging, CA USA). Band intensities were analyzed using Quantity One, version 4.6.3 (Bio Rad).
Results
Rosiglitazone improves insulin sensitivity Short term treatment with rosiglitazone 4 mg BD improved insulin sensitivity in the absence of any changes in body weight (Table I) . 
Identification of differentially expressed proteins
In total 71 unknown spots were selected and excised manually from gels of both control and In the remaining 5 spots no significant identification was obtained. The excised spots were selected among the differentially expressed proteins with consistent changes but also among other proteins. Our gel spot identification yield was 92% with several proteins appearing at multiple positions on the gels.
Characterization of adipogenic proteins correlated with improved insulin sensitivity Rosiglitazone induced changes in expression levels of multiple proteins and their fold changes were calculated by dividing the average spot quantities recorded in adipose tissue exposed to rosiglitazone for 14 days with quantities recorded in control samples. Among the proteins which showed significant (p<0.05) higher expression level, when rosiglitazone treated adipose tissue samples were compared to untreated control adipose tissue, collagen a-1(VI) chain precursor (COL6A1), nidogen-1 precursor (entactin), laminin gamma-1 chain precursor (laminin B2 chain) and collagen a-2(VI) chain precursor (COL6A2) showed >4 fold changes. Figure-2 shows differential expression of COL6A1 in human adipose tissue in response to rosiglitazone. Other adipogenic proteins showing significant changes in expression in response to rosiglitazone includes cytoskeletal proteins (lamin A/C, vimentin, tropomyosin 3, tropomyosin 4, gelsolin, actin, tubulin â-1 chain), extracellular matrix proteins (galectin-1, integrin a-IIb precursor, integrin â-3 precursor), signaling proteins (calmodulin), antioxidants (ferritin light chain, heat-shock protein â-5, heat-shock protein â-1), ER stress proteins (endoplasmin, 78 kDa glucose-regulated protein precursor) and others (glyceraldehyde-3-phosphate dehydrogenase, a enolase). The increased expression of lamin A/C and protein disulfide-isomerase (PDI) was further verified by Western blotting (Figure-3 ).
Discussion
The identification of novel biomarkers associated with insulin resistance is an essential research goal in diabetes research. In the present study, we have taken advantage of the 2 D gel based proteomics approaches to identify such targets using rosiglitazone as a tool for insulin sensitizer. We have identified clusters of proteins exhibiting altered expression during the process of amelioration of insulin resistance driven by the potent TZD, rosiglitazone. Our report provides a molecular snapshot of the mechanism of action of the TZD class of insulin sensitizers regulating adipogenesis in human adipose tissue.
In humans, the onset of the antidiabetic action of rosiglitazone is slow and it is commonly believed that a treatment period of 3 months is needed. However, insulin sensitization has been J Bangladesh Soc Physiol. 2009 Dec;4(2): 34- 43 38
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Article demonstrated using pioglitazone within three weeks as well 16, 17 . We observed a modest but significant decrease in plasma glucose and insulin after 14 days of treatment with rosiglitazone. Plasma NEFA was significantly reduced after rosiglitazone treatment, likely to represent acute reduction in the release of NEFAs from adipose tissue depots, with only minor changes in plasma TG concentrations 16 . Correlating to these biochemical findings we have identified multiple adipogenic proteins showing differential expression in response to rosiglitazone treatment.
PPARã is the master regulator of adipogenesis and a direct role of extracellular matrix (ECM) in regulating gene expression and promoting adipocyte differentiation has been proposed 6, 18 . The ECM of adipose tissue interconnects adipocytes and gives rise to fat cell clusters in vitro and to fat lobules of adipose tissue in vivo. During adipocyte differentiation drastic changes occur in cell morphology, cytoskeletal components, and the level and type of secreted ECM components. An early ultrastructural change seen in in vivo adipocyte differentiation is the deposition of collagen at the cell-ECM border and extracellular basement membrane biogenesis 6, 19 . It has been reported that inhibition of collagen synthesis prevented the preadipocytes from differentiation 20 . All types of collagen were secreted from adipocytes at any time point during differentiation but with a different profile 21 . During the differentiation of adipocytes, the expressions of type I and type III collagens decreased, while the synthesis and secretion of type IV collagen increased 19, [22] [23] [24] . The a2 chain of type VI collagen increased at confluence and post confluence and then gradually decreased at a time when mRNAs encoding lipogenic enzymes increased dramatically 9, 25 , while extracellular nidogen 1 and laminin (LN) increased 22, 26 . Laminin expression is tightly coupled with lipid accumulation in adipocytes and unilocular rounded or three dimensional morphology of adipocytes 23, 27 and our study shows a >3 fold changes in expression of laminin B2 (LAMB2) chain in response to rosigltazone. Another extracellular protein, galectin 1 is an adipocyte specific secreted protein with pleotropic functions and showed unambiguous up regulation during 3T3 L1 adipocyte differentiation 21 . Adipocyte differentiation is also regulated by intermediate filaments, such as lamin A/Cs, which form a meshwork of filaments on the inside of the nuclear membrane and are encoded by the LMNA gene. Recent studies have reported association between variation at the LMNA gene and type 2 diabetes in ethnically diverse populations 28, 29 .
In human subcutaneous adipose tissue, expression of lamin A/C protein increases during preadipocyte differentiation 30 . Over expression of the earliest marker of adipocyte differentiation, a2(VI) collagen along with a1(VI) collagen, galectin 1, nidogen 1, lamin A/C and LAMB2 suggests that one of the mechanisms behind insulin sensitization of rosiglitazone may involve differentiation and remodeling of human adipocytes with concurrent increase in lipid storage. Remodeling and expansion of adipose tissue by the TZDs, which offers 'storage space' for lipids, is believed to offset ectopic lipid accumulation in muscle and liver, thereby contributing to insulin sensitivity 31, 32 . The increase in fat mass in response to TZD occurs due to increased number of small adipocytes in fat depots, enhanced lipogenic activity in white adipose tissue and depot-specific redistribution resulting in a remodeling of the adipose depots, especially the visceral adipose depots. The higher lipid storage capacity of the new, small, insulin-sensitive adipocytes likely serves to lower circulating plasma FFA levels and visceral triglyceride levels, which possibly accounts for the decrease in insulin resistance 33, 34 .
In addition to the ECM proteins, our proteomic data confirm rosiglitazone-induced differential expression of several other proteins that regulate adipogenesis. Recent evidences suggest that increased oxidative stress in accumulated fat is an early indicator of metabolic syndrome and the redox state in adipose tissue is a potentially useful therapeutic target for obesity-associated metabolic syndrome 35, 36 . In the present study, ferritin light chain appeared as new spot after treatment with rosiglitazone for 14 days but was barely visible in control samples. It has been previously shown that over expression of ferritin exert an antioxidant function and limit iron toxicity during adipocyte differentiation 37 . Other upregulated chaperones with antioxidative function include a crystallin B chain and HSP27. The induction of these proteins has been reported during adipogenesis of human adipose derived stem cells 38 . In addition, aB crystallin expression has been found to decrease in adipose tissue of diabetic rat 39 . An intriguing function of HSP27 and a crystallin B chain is the ability to increase the resistance of cells to oxidative injuries. The expression of these chaperones correlates with decreased levels of reactive oxygen species (ROS) and nitric oxide 40 . In adipocytes from obese mice ROS can induce enoplasmic reticulum (ER) stress coupled with PKRlike eukaryotic initiation factor 2 (eIF2a) kinase (PERK) activation, eIF2 phosphorylation, and GRP78 induction 41, 42 . Recently it has been shown that ER stress, evidenced by induction of GRP78, suppresses adipocyte differentiation 43 . ER stress also induces expression of endoplasmin (GRP94) in adipocytes 44 . Considering the fact that ER stress inhibits adipogenesis and reduces insulin sensitivity, our findings of decreased expression of GRP78 and endoplasmin in response to rosiglitazone treatment suggests reduction of ER stress and consequently improved adipogenesis and enhanced insulin sensitivity in human adipose tissue.
In our 2 D gel system the spots corresponding to tropomyosin 3 and tropomyosin 4 showed decreased expression in response to rosiglitazone. Other proteomic studies showed that the expression of tropomyosin changes during adipocyte differentiation suggesting an important role for tropomyosin in maintaining cell shape 45, 46 . Tropomyosins increase filament stiffness, stabilize actin filaments by protecting them against the severing action of gelsolin and cofilin and more importantly, influence myosin mechanochemistry 47, 48 . Gelsolin, an actin binding protein, respond to Ca 2+ and phosphatidylinositol 4,5 bisphosphate (PIP 2 ) and control actin organization by severing filaments, capping filament ends and nucleating actin assembly [49] [50] [51] . During adipogenesis expression of actin and tubulin decreases while levels of vimentin increase 52, 53 . It has also been shown that during adipose conversion, the extended wavy, fibrillar organization of vimentin in undifferentiated cells is altered 54, 55 .
Calmodulin showed a > 2 fold increase in expression level in response to rosiglitazone. In addition to the fundamental role of Ca 2+ /calmodulin in GLUT4 vesicle docking and fusion in 3T3 L1 cells 56 , calmodulin exert a positive regulatory role in adipogenesis through phosphorylation of calmodulin-dependent protein kinase II 57, 58 . With respect to glycolytic enzymes, the increased expression of GAPDH and enolase is in agreement with enhanced glycolytic activity and also fatty acid synthesis during adipocyte differentiation 59 . Alpha enolase is a multifunctional enzyme 60 and has been reported as secreted protein from 3T3 L1 adipocytes with a single transmembrane helix 21 . The cell surface protein nature of the a enolase may render it to serve as a receptor for plasminogen and there is evidence that the plasminogen cascade is required for adipocyte differentiation 60, 61 .
Conclusion
In conclusion, the present study for the first time shows that improved insulin sensitivity in human individuals induced by short term treatment with rosiglitazone corresponds to differential expression of multiple adipogenic proteins between control and treated adipose tissue samples. Treatment of obese subjects with rosiglitazone for 14 days results in a marked reduction of plasma glucose, insulin and NEFA without body weight gain. Regulation of extracellular matrix proteins, redox proteins and chaperones, and proteins involved in lipid, carbohydrate and iron metabolism might result in the improvement of adipogenesis and thus insulin sensitivity. Furthermore, modulation of proteins involved in maintaining cellular and cytoskeleton structure of the adipocyte and signaling pathways can be associated with the remodeling of the adipose depots.
